A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Shannon McWeeney, Lucy C. Pemberton, Marc Loriaux, Kristina Vartanian, Stephanie G. Willis, Gregory Yochum, Beth Wilmot, Yaron Turpaz, Raji Pillai, Brian Druker, Jennifer L. Snead, Mary MacPartlin, Stephen G. O'Brien, Junia V. Melo, Thoralf Lange, Christina (Chris) Harrington, Michael W N Deininger

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (<36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65%Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.

Original languageEnglish (US)
Pages (from-to)315-325
Number of pages11
JournalBlood
Volume115
Issue number2
DOIs
StatePublished - Jan 14 2010

Fingerprint

Leukemia, Myeloid, Chronic Phase
Transcriptome
Gene expression
Cytogenetics
Classifiers
Metaphase
Catenins
Biomarkers
Bioinformatics
Gene Expression Profiling
Toxicity
Computational Biology
Genes
Imatinib Mesylate
Therapeutics
Learning

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. / McWeeney, Shannon; Pemberton, Lucy C.; Loriaux, Marc; Vartanian, Kristina; Willis, Stephanie G.; Yochum, Gregory; Wilmot, Beth; Turpaz, Yaron; Pillai, Raji; Druker, Brian; Snead, Jennifer L.; MacPartlin, Mary; O'Brien, Stephen G.; Melo, Junia V.; Lange, Thoralf; Harrington, Christina (Chris); Deininger, Michael W N.

In: Blood, Vol. 115, No. 2, 14.01.2010, p. 315-325.

Research output: Contribution to journalArticle

McWeeney, S, Pemberton, LC, Loriaux, M, Vartanian, K, Willis, SG, Yochum, G, Wilmot, B, Turpaz, Y, Pillai, R, Druker, B, Snead, JL, MacPartlin, M, O'Brien, SG, Melo, JV, Lange, T, Harrington, CC & Deininger, MWN 2010, 'A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib', Blood, vol. 115, no. 2, pp. 315-325. https://doi.org/10.1182/blood-2009-03-210732
McWeeney, Shannon ; Pemberton, Lucy C. ; Loriaux, Marc ; Vartanian, Kristina ; Willis, Stephanie G. ; Yochum, Gregory ; Wilmot, Beth ; Turpaz, Yaron ; Pillai, Raji ; Druker, Brian ; Snead, Jennifer L. ; MacPartlin, Mary ; O'Brien, Stephen G. ; Melo, Junia V. ; Lange, Thoralf ; Harrington, Christina (Chris) ; Deininger, Michael W N. / A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. In: Blood. 2010 ; Vol. 115, No. 2. pp. 315-325.
@article{c45689ec87ec4a13a5f9a5d001742e52,
title = "A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib",
abstract = "In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (<36{\%} Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65{\%}Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88{\%} of responders and83{\%} of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.",
author = "Shannon McWeeney and Pemberton, {Lucy C.} and Marc Loriaux and Kristina Vartanian and Willis, {Stephanie G.} and Gregory Yochum and Beth Wilmot and Yaron Turpaz and Raji Pillai and Brian Druker and Snead, {Jennifer L.} and Mary MacPartlin and O'Brien, {Stephen G.} and Melo, {Junia V.} and Thoralf Lange and Harrington, {Christina (Chris)} and Deininger, {Michael W N}",
year = "2010",
month = "1",
day = "14",
doi = "10.1182/blood-2009-03-210732",
language = "English (US)",
volume = "115",
pages = "315--325",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

AU - McWeeney, Shannon

AU - Pemberton, Lucy C.

AU - Loriaux, Marc

AU - Vartanian, Kristina

AU - Willis, Stephanie G.

AU - Yochum, Gregory

AU - Wilmot, Beth

AU - Turpaz, Yaron

AU - Pillai, Raji

AU - Druker, Brian

AU - Snead, Jennifer L.

AU - MacPartlin, Mary

AU - O'Brien, Stephen G.

AU - Melo, Junia V.

AU - Lange, Thoralf

AU - Harrington, Christina (Chris)

AU - Deininger, Michael W N

PY - 2010/1/14

Y1 - 2010/1/14

N2 - In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (<36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65%Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.

AB - In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (<36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65%Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.

UR - http://www.scopus.com/inward/record.url?scp=75649084233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649084233&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-210732

DO - 10.1182/blood-2009-03-210732

M3 - Article

C2 - 19837975

AN - SCOPUS:75649084233

VL - 115

SP - 315

EP - 325

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -